Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8690 in Rheumatoid Arthritis
NCT07895524Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2026
- Primary completion
- Oct 2027
01
Overview
A Phase 2 trial of MK-8690 in rheumatoid arthritis (RA), sponsored by Merck & Co.. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
MK-8690
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07895524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07895524.